Interventions of Interest
For questions please contact [email protected].
- baxdrostat (AstraZeneca)
- lorundrostat (Mineralys Therapeutics, Inc.)
Hypertension
An assessment of baxdrostat and lorundrostat
Public Meeting
October 2026
Assessment Status
Open
Upcoming Milestone
Model Analysis PlanView
Main Review
October 29, 2026
Midwest CEPAC
The Midwest CEPAC 2026 public meeting on aldosterone synthase inhibitors for hypertension
ICER STAKEHOLDER OUTREACH AND PUBLIC COMMENTERS LIST
ICER receives input on its reviews from multiple stakeholders, including patients and their families, patient advocacy organizations, clinicians, clinical societies, insurers, and drugmakers. We invite the public to submit recommendations for stakeholders in any of these categories.
The following is a list of organizations from which ICER has requested input, as well as those that have provided unsolicited public comments during the review. Some organizations on the list may appear only because they were invited to provide input, and it should not be assumed that they have responded to ICER’s outreach or agreed to participate in this review.
- American Heart Association
- American Stroke Association
- AstraZeneca
- Black Women’s Health Imperative
- Family Heart Foundation
- Healthy Women
- Mended Hearts
- Mineralys Therapeutics
- National Kidney Foundation
- No Patient Left Behind
- Partnership to Advance Cardiovascular Health
- Society for Women’s Health Research
- WomenHeart
To protect patient confidentiality, ICER does not routinely name individual patients or care partners who provided us with input and feedback.
None of these stakeholders are responsible for the final content of ICER’s report, and it should not be assumed that they support any part of the report, which is solely the work of the ICER team and its affiliated researchers.
Related Assessments & Policy Papers.
High Cholesterol
Feb 2021High Cholesterol: PCSK9s
Feb 2019
06/23/2026
Model Analysis Plan
Please find the model analysis plan here:
10/02/2026
Evidence Report
10/29/2026
Evidence Presentation
11/30/2026
Public Comments
Closed